Access Industries returned to back the cancer therapy developer's $70m series B round, having previously contributed to a $55m series A round in 2015.

US-based immuno-oncology company Neon Therapeutics raised $70m in series B funding on Thursday from investors including conglomerate Access Industries.

The round was led by Partner Fund Management, with participation from financial services conglomerate Fidelity Management & Research Company, Third Rock Ventures, Wellington Management Company, Inbio Ventures and Nextech Invest.

Neon Therapeutics is working on therapeutic vaccines and T-cell therapies to treat cancer. The company’s approach uses the body’s own immune system to target proteins called neoantigens which are caused by…